NO20072318L - Okular levering av polymere leveringsformuleringer - Google Patents

Okular levering av polymere leveringsformuleringer

Info

Publication number
NO20072318L
NO20072318L NO20072318A NO20072318A NO20072318L NO 20072318 L NO20072318 L NO 20072318L NO 20072318 A NO20072318 A NO 20072318A NO 20072318 A NO20072318 A NO 20072318A NO 20072318 L NO20072318 L NO 20072318L
Authority
NO
Norway
Prior art keywords
delivery
composition
mammal
thermoplastic polymer
polymeric
Prior art date
Application number
NO20072318A
Other languages
English (en)
Inventor
Eric Dadey
Christopher M Lindemann
Stephen L Warren
Richard L Norton
Original Assignee
Qlt Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qlt Usa Inc filed Critical Qlt Usa Inc
Publication of NO20072318L publication Critical patent/NO20072318L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det beskrives en flytbar sammensetning som er egnet for bruk som et implantat med kontrollert frigjøring. Den flytbare sammensetningen kan administreres øyeområdet hos et pattedyr. Sammensetningen inkluderer: (a) en bionedbrytbar, bioforenlig termoplastisk polymer som i det minste i alt vesentlig er uløselig i vandig medium, vann eller kroppsvæske; (b) et biologisk middel, en metabolitt derav, et biologisk akseptabelt salt derav eller et formedikament derav; og (c) en bioforenlig organisk væske ved standard temperatur og trykk, i hvilken den termoplastiske polymeren er løselig. Det beskrives også fremgangsmåter for medisinsk behandling som inkluderer administrering av den flytbare sammensetningen i øyeområdet hos et pattedyr.
NO20072318A 2004-10-04 2007-05-04 Okular levering av polymere leveringsformuleringer NO20072318L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61572704P 2004-10-04 2004-10-04
US62863004P 2004-11-17 2004-11-17
US62913304P 2004-11-18 2004-11-18
PCT/US2005/035865 WO2006041942A2 (en) 2004-10-04 2005-10-04 Ocular delivery of polymeric delivery formulations

Publications (1)

Publication Number Publication Date
NO20072318L true NO20072318L (no) 2007-05-04

Family

ID=36148882

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072318A NO20072318L (no) 2004-10-04 2007-05-04 Okular levering av polymere leveringsformuleringer

Country Status (10)

Country Link
US (1) US20060210604A1 (no)
EP (1) EP1804751A2 (no)
JP (1) JP2008520547A (no)
KR (1) KR20070083941A (no)
AU (1) AU2005294382A1 (no)
BR (1) BRPI0516308A2 (no)
CA (1) CA2582374A1 (no)
MX (1) MX2007003789A (no)
NO (1) NO20072318L (no)
WO (1) WO2006041942A2 (no)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
AU2004296376B2 (en) 2003-12-05 2010-03-04 Bristol-Myers Squibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
US20080220049A1 (en) * 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
WO2006078320A2 (en) 2004-08-04 2006-07-27 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US8637070B2 (en) 2005-02-09 2014-01-28 Santen Pharmaceutical Co., Ltd. Rapamycin formulations and methods of their use
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
GB0523964D0 (en) * 2005-11-24 2006-01-04 Arakis Ltd The treatment of ophthalmic diseases
WO2007076358A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
EP2001438A2 (en) 2006-02-09 2008-12-17 Macusight, Inc. Stable formulations, and methods of their preparation and use
US20080261893A1 (en) * 2006-02-24 2008-10-23 Denise Barbut Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing
ES2563288T3 (es) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
JP5823093B2 (ja) * 2006-03-28 2015-11-25 ジャヴェリン ファーマシューティカルズ インコーポレイテッド 低投与量のジクロフェナク及びβ−シクロデキストリンの配合物
US20070232567A1 (en) * 2006-03-28 2007-10-04 Curtis Wright Formulations Of Low Dose Non-Steroidal Anti-Inflammatory Drugs And Beta-Cyclodextrin
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
WO2008015695A2 (en) * 2006-05-15 2008-02-07 Sun Pharmaceutical Industries Limited Inclusion complex of olopatadine and cyclodextrin
US20070275098A1 (en) * 2006-05-19 2007-11-29 T.R.P. Company, Inc, A Nevada Corporation Formulation and methodology for the treatment for eye impairment symptoms
RU2467747C2 (ru) * 2006-07-25 2012-11-27 Векта Лтд. Композиции и способы для ингибирования секреции желудочной кислоты с использованием производных малых дикарбоновых кислот в сочетании с ppi
US8039010B2 (en) * 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8470332B2 (en) 2006-11-22 2013-06-25 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
EP2121107B1 (en) * 2006-12-18 2012-10-31 Eatlittle Inc. Device for delivery of a substance
US8846073B2 (en) 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
FI3660073T3 (fi) * 2007-02-15 2023-09-11 Tolmar International Ltd Matalan purskeen poly(laktidi-ko-glykolidi)
EP2131651B1 (en) * 2007-03-12 2013-05-22 Sarentis Therapeutics, Inc. Topical corneal analgesia using neurotensin receptor agonists
US8092825B2 (en) * 2007-03-29 2012-01-10 The University Of Tennessee Research Foundation Glycan binding proteins as therapeutic targets for retinal disorders and treatment methods based thereon
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
EP2030610A1 (en) * 2007-08-31 2009-03-04 Archimedes Development Limited Non-aqueous pharmaceutical compositions
WO2009027697A2 (en) 2007-08-31 2009-03-05 Archimedes Development Limited Non-aqueous pharmaceutical compositions
JP5382879B2 (ja) * 2007-12-13 2014-01-08 国立大学法人九州大学 薬物含有ナノ粒子
EP2222281B1 (en) 2007-12-20 2018-12-05 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
MX2010008874A (es) 2008-02-14 2010-09-22 Bristol Myers Squibb Co Terapeuticos dirigidos a base de proteinas manipuladas que se unen al receptor de factor de crecimiento epidermico.
US8420114B2 (en) * 2008-04-18 2013-04-16 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
US20090263489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation
US9132119B2 (en) * 2008-04-18 2015-09-15 Medtronic, Inc. Clonidine formulation in a polyorthoester carrier
AR071874A1 (es) 2008-05-22 2010-07-21 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
JP2012504135A (ja) 2008-09-27 2012-02-16 ジャイナ ファーマシューティカルズ，インコーポレーテッド 経口適用および局所適用のための脂質系薬学的調製物、ならびにそれらの組成物、方法、および使用
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
US8815971B2 (en) 2008-12-22 2014-08-26 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US8822610B2 (en) 2008-12-22 2014-09-02 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US20100204325A1 (en) * 2009-02-11 2010-08-12 Allergan, Inc. Valproic acid drug delivery systems and intraocular therapeutic uses thereof
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
WO2010123574A1 (en) 2009-04-23 2010-10-28 Atrp Solutions Inc Star macromolecules for personal and home care
US8173750B2 (en) 2009-04-23 2012-05-08 ATRP Solutions, Inc. Star macromolecules for personal and home care
US9783628B2 (en) 2009-04-23 2017-10-10 ATRP Solutions, Inc. Dual-mechanism thickening agents for hydraulic fracturing fluids
WO2012071476A2 (en) 2010-11-24 2012-05-31 David Haffner Drug eluting ocular implant
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
CN102573813B (zh) 2009-08-18 2013-11-06 国立大学法人东北大学 持续药物传递系统
US20110097380A1 (en) * 2009-10-28 2011-04-28 Warsaw Orthopedic, Inc. Clonidine formulations having antimicrobial properties
JP5815552B2 (ja) 2009-12-08 2015-11-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 眼疾患を治療する化合物および方法
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
WO2011150133A2 (en) 2010-05-26 2011-12-01 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
HUE057236T2 (hu) 2010-05-31 2022-04-28 Farm Rovi Lab Sa Készítmények befecskendezhetõ in-situ biológiailag lebontható implantátumokhoz
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
US9272044B2 (en) * 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513267B (en) * 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
WO2012070033A1 (en) 2010-11-26 2012-05-31 University Of The Witwatersrand, Johannesburg An implant for the controlled release of pharmaceutically active agents
US9018202B2 (en) * 2010-12-03 2015-04-28 Allergan, Inc. Methods for treating diseases of the retina
US9587064B2 (en) 2010-12-08 2017-03-07 ATRP Solutions, Inc. Salt-tolerant star macromolecules
US20130317058A1 (en) * 2011-02-18 2013-11-28 M/S. Appasamy Associates Ophthalmic composition for enabling dilation of pupils
PL2697257T3 (pl) 2011-04-13 2017-04-28 Bristol-Myers Squibb Company Białka fuzyjne fc o nowatorskim układzie lub zawierające nowatorskie łączniki
WO2012158678A1 (en) 2011-05-17 2012-11-22 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
LT2717914T (lt) * 2011-06-10 2020-03-25 Ramscor, Inc. Sulėtinto atpalaidavimo kompozicijos, skirtos baltymų pateikimui į akį, ir jų paruošimo būdai
US20130035338A1 (en) * 2011-08-05 2013-02-07 Gordon Tang Eyelid treatment
US9522951B2 (en) 2011-10-31 2016-12-20 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
US20150051558A1 (en) * 2012-04-05 2015-02-19 University Of Central Florida Research Foundation, Inc. Composition and method for corneal proliferation
KR101312926B1 (ko) * 2012-05-14 2013-10-01 크루셜텍 (주) 로봇청소기의 감지장치 및 감지방법
CA2882832C (en) 2012-08-30 2021-08-24 ATRP Solutions, Inc. Dual mechanism thickening agents for hydraulic fracturing fluids
DK3835310T3 (da) 2012-09-13 2024-06-03 Bristol Myers Squibb Co Fibronektinbaserede skeletdomæneproteiner, der binder til myostatin
EP2897593A4 (en) * 2012-09-20 2016-04-06 Akina Inc BIOABCABLE MICRO CAPSULES WITH A FILLING MATERIAL
RU2676102C2 (ru) 2012-09-27 2018-12-26 Аллерган, Инк. Биодеградируемые системы доставки лекарственных средств для долговременного высвобождения белков
ES2797376T3 (es) 2013-01-24 2020-12-02 Palvella Therapeutics Inc Composiciones para la administración transdérmica de inhibidores de mTOR
WO2014120891A2 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
CN105263978B (zh) 2013-02-04 2018-04-17 Atrp解决方案公司 耐盐星形大分子
EP2953968B1 (en) 2013-02-06 2018-07-25 Bristol-Myers Squibb Company Fibronectin type iii domain proteins with enhanced solubility
EP3299378B1 (en) 2013-02-12 2019-07-31 Bristol-Myers Squibb Company High ph protein refolding methods
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
WO2014182620A1 (en) 2013-05-06 2014-11-13 Kaohsiung Chang Gung Memorial Hospital Pharmaceutical composition and uses thereof
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
RU2650614C2 (ru) 2013-10-31 2018-04-16 Аллерган, Инк. Внутриглазные имплантаты, содержащие простамид, и способы их применения
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
EP3148491B1 (en) 2014-05-29 2020-07-01 Glaukos Corporation Implants with controlled drug delivery features and manufacturing method for said implants
JP6689210B2 (ja) 2014-07-03 2020-04-28 パイロット ポリマー テクノロジーズ， インク． 界面活性剤相溶性星形高分子
JP6371463B2 (ja) 2014-07-17 2018-08-08 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 即時放出性乱用抑止性液体充填剤形
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
AU2015341490C1 (en) 2014-11-07 2021-03-11 Indivior Uk Limited Buprenorphine dosing regimens
US10350223B2 (en) 2015-03-03 2019-07-16 Richard W. Yee Compositions and methods for treating ocular diseases
EP3272362B1 (en) 2015-03-18 2023-12-13 Santen Pharmaceutical Co., Ltd. Sustained-release pharmaceutical composition
US11213480B1 (en) 2015-08-06 2022-01-04 Hikma Pharmaceuticals International Limited Phenylephrine hydrochloride ready-to-use solution
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
JP6967222B2 (ja) * 2015-12-17 2021-11-17 リンク・ジェノミクス株式会社 脈絡膜新生血管抑制剤又はドルーゼン抑制剤およびその評価又はスクリーニング方法
EP3442479A1 (en) 2016-04-20 2019-02-20 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
CA3039106A1 (en) 2017-01-20 2018-07-26 Kedalion Therapeutics, Inc. Piezoelectric fluid dispenser
WO2018151849A1 (en) 2017-02-17 2018-08-23 Privo Technologies, Inc. Particle-based multi-layer therapeutic delivery device and method
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
BR102017016440A2 (pt) 2017-07-31 2019-03-19 Universidade Federal Do Rio Grande Do Sul Composição para terapia gênica do sistema nervoso central, processo de obtenção e uso da mesma
CN108379289A (zh) * 2018-04-03 2018-08-10 高永鹏 一种用于牛、羊眼部疾病的喷剂
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
US11679028B2 (en) * 2019-03-06 2023-06-20 Novartis Ag Multi-dose ocular fluid delivery system
US12097145B2 (en) 2019-03-06 2024-09-24 Bausch + Lomb Ireland Limited Vented multi-dose ocular fluid delivery system
WO2021138646A1 (en) * 2020-01-03 2021-07-08 Privo Technologies, Inc. Systems and pharmaceutical compositions for treatment by direct injection of a targeted population of cells
WO2021212038A1 (en) 2020-04-17 2021-10-21 Kedalion Therapeutics, Inc. Hydrodynamically actuated preservative free dispensing system having a collapsible liquid reservoir
CN116528851A (zh) * 2020-06-26 2023-08-01 普渡研究基金会 用于长期眼部递送的灰黄霉素的药物制剂
FI20215186A1 (en) * 2021-02-19 2022-08-20 Rebio Tech Oy Compositions for ophthalmic treatment
US11779553B1 (en) 2022-11-28 2023-10-10 Atif B. D. Collins Methods and devices for treatment of eyelid ptosis

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3416530A (en) * 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US4179497A (en) * 1973-12-17 1979-12-18 Merck & Co., Inc. Solid state ophthalmic medication
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US3963025A (en) * 1974-09-16 1976-06-15 Alza Corporation Ocular drug delivery device
US4053580A (en) * 1975-01-01 1977-10-11 G. D. Searle & Co. Microsealed pharmaceutical delivery device
US4164559A (en) * 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US4249531A (en) * 1979-07-05 1981-02-10 Alza Corporation Bioerodible system for delivering drug manufactured from poly(carboxylic acid)
US4316885A (en) * 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4346709A (en) * 1980-11-10 1982-08-31 Alza Corporation Drug delivery devices comprising erodible polymer and erosion rate modifier
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4612302A (en) * 1983-11-14 1986-09-16 Brigham And Women's Hospital Clinical use of somatostatin analogues
US4684620A (en) * 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
DE3678308D1 (de) * 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
US4853371A (en) * 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US5632727A (en) * 1988-10-03 1997-05-27 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5182258A (en) * 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5487897A (en) * 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US5130307A (en) * 1990-09-28 1992-07-14 American Home Products Corporation Aminoesters of rapamycin
US5233036A (en) * 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5120842A (en) * 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) * 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5102876A (en) * 1991-05-07 1992-04-07 American Home Products Corporation Reduction products of rapamycin
US5138051A (en) * 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
US5118677A (en) * 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
DE69220317T2 (de) * 1991-10-01 1997-10-16 Takeda Chemical Industries Ltd Mikropartikeln-Zusammenfassung zur verlängerten Freigabe und Herstellung derselbe
AU2605592A (en) * 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5151413A (en) * 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5164399A (en) * 1991-11-18 1992-11-17 American Home Products Corporation Rapamycin pyrazoles
US5221740A (en) * 1992-01-16 1993-06-22 American Home Products Corporation Oxepane isomers of rapamycin useful as immunosuppressive agents
US5177203A (en) * 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
EP0560014A1 (en) * 1992-03-12 1993-09-15 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
JP3277342B2 (ja) * 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5242910A (en) * 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
MY113268A (en) * 1992-12-29 2002-01-31 Insite Vision Incorporated Plasticized bioerodible controlled delivery system
US6221958B1 (en) * 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5863985A (en) * 1995-06-29 1999-01-26 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US6447196B1 (en) * 1993-05-12 2002-09-10 George A. Arkwright Adhesive fastener assembly
US5373014A (en) * 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5681873A (en) * 1993-10-14 1997-10-28 Atrix Laboratories, Inc. Biodegradable polymeric composition
PT754032E (pt) * 1994-04-08 2002-05-31 Atrix Lab Inc Composicoes liquidas para difusao
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6447796B1 (en) * 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US5463048A (en) * 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5718922A (en) * 1995-05-31 1998-02-17 Schepens Eye Research Institute, Inc. Intravitreal microsphere drug delivery and method of preparation
ATE210843T1 (de) * 1995-06-02 2001-12-15 Jds Uniphase Photonics C V Kaskadenartige thermooptische vorrichtung
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
HU224814B1 (en) * 1995-12-28 2006-02-28 Mitsubishi Pharma Corp Use of propane-1,3-diol derivative for the preparation of a medicament useful for the topical treating of inflammatory and immune diseases
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
PT839525E (pt) * 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
US6342250B1 (en) * 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
FR2770694B1 (fr) * 1997-11-03 1999-12-17 Commissariat Energie Atomique Dispositif de laser a gaz et a moyens de purification de gaz integres
US6261583B1 (en) * 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6355657B1 (en) * 1998-12-30 2002-03-12 Atrix Laboratories, Inc. System for percutaneous delivery of opioid analgesics
US6264971B1 (en) * 1999-11-04 2001-07-24 Btg International Limited Ocular insert
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
DE50112157D1 (de) * 2000-01-11 2007-04-19 Roland Bodmeier Kit zur implantation enthaltend eine trägerphase und ein lösungsmittel
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US6399625B1 (en) * 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
MXPA04001524A (es) * 2001-08-22 2004-05-31 Wyeth Corp 29-enoles de rapamicina.
WO2003018574A1 (en) * 2001-08-22 2003-03-06 Wyeth Rapamycin dialdehydes
CN1684663A (zh) * 2002-07-31 2005-10-19 阿尔萨公司 可注射的多模式聚合物储库组合物以及其用途
AU2003272471B2 (en) * 2002-09-18 2010-10-07 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
EP1622540A4 (en) * 2003-03-11 2009-12-30 Qlt Usa Inc FORMULATIONS FOR CELL-PLAN-DEPENDENT CANCER
CA2539324A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery

Also Published As

Publication number Publication date
EP1804751A2 (en) 2007-07-11
MX2007003789A (es) 2007-07-20
BRPI0516308A2 (pt) 2010-06-15
WO2006041942A3 (en) 2009-04-23
AU2005294382A1 (en) 2006-04-20
US20060210604A1 (en) 2006-09-21
WO2006041942A2 (en) 2006-04-20
CA2582374A1 (en) 2006-04-20
KR20070083941A (ko) 2007-08-24
JP2008520547A (ja) 2008-06-19

Similar Documents

Publication Publication Date Title
NO20072318L (no) Okular levering av polymere leveringsformuleringer
Nyitray et al. Polycaprolactone thin-film micro-and nanoporous cell-encapsulation devices
CN103463675B (zh) 一种抗菌抗肿瘤骨科植入材料及其制备方法
JP2018504167A5 (no)
CN108136070A (zh) 创伤后骨关节炎的预防性治疗
WO2004081196A3 (en) Formulations for cell- schedule dependent anticancer agents
NO20084471L (no) Nasolakrimalt dreneringssystemimplantater for legemiddelterapi
PJ et al. Biomedical applications of polymers—An overview
CN105232532A (zh) 维生素c和维生素k的组合及其用途
RU2016110605A (ru) Способ получения инъекционного гидрогеля на основе гиалуроновой кислоты, содержащего лидокаин и щелочной агент, стерилизованного теплом
Chakraborty et al. Engineering multifunctional adhesive hydrogel patches for biomedical applications
JP6533235B2 (ja) 生物医学的応用における使用のためのシクロデキストリンを組み入れたコラーゲンマトリクスを含む組成物
Gopan et al. The use of cellulose, chitosan and hyaluronic acid in transdermal therapeutic management of obesity: A review
Alshammari et al. An update on microneedle in insulin delivery: quality attributes, clinical status and challenges for clinical translation
Li et al. Advanced hydrogel material for meniscus repair
WO2008088536A8 (en) Differential drug release from a medical device
ATE267843T1 (de) Verfahren zur herstellung von selbstvernetzten hyaluronsäuren und deren derivaten mittels superkritischer anti-lösungsmittel
WO2010039970A3 (en) Applying shear stress for disease treatment
Zhou et al. Nanomaterials in the sports rehabilitation of basketball players after anterior cruciate ligament reconstruction
CN107809977A (zh) 用于治疗干型和湿型年龄相关性黄斑变性或糖尿病视网膜病变的可注射的多孔装置
CN106177970B (zh) 罗哌卡因注射用制剂及其制备方法和应用
CN109199562A (zh) 一种骨水泥骨折固定装置及其使用方法
CN102441171A (zh) 一种局部用温敏型抗菌药缓释剂及其制备方法
Tören Regenerative Medicine and Tissue Engineering: Advancements and Challenges in Cell-Based Therapies
Sathisaran 3D printing and bioprinting in the battle against diabetes and its chronic complications

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application